HE4 在评估上皮性卵巢癌和子宫内膜癌中的新兴作用。
The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomas.
机构信息
Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
出版信息
Oncology (Williston Park). 2013 Jun;27(6):548-56.
Abstract
HE4 (human epididymis protein 4) is overexpressed in both ovarian and endometrial cancers. Levels of the shed HE4 protein are elevated in sera from ovarian and endometrial cancer patients. HE4 is less frequently elevated than cancer antigen 125 (CA 125) in benign gynecologic conditions and is found in a fraction of endometrial and ovarian cancers that lack CA 125 expression. Consequently, HE4 has emerged as an important biomarker that complements CA 125 in discriminating between benign and malignant pelvic masses, monitoring response to treatment, and detecting recurrences of both ovarian and endometrial cancer. The "risk of ovarian malignancy algorithm" (ROMA) incorporates CA 125, HE4, and menopausal status to distinguish benign from malignant adnexal masses, and has been approved by the US Food and Drug Administration to aid in referring patients who are likely to have ovarian cancer to specially trained gynecologic oncologists for surgery. HE4 also promises to augment the sensitivity of CA 125 for detecting early-stage ovarian cancer. In this review, we discuss the discovery and biologic significance of HE4 and evaluate available evidence regarding the utility of HE4 as a biomarker for ovarian and endometrial cancer.
摘要
人附睾蛋白 4（HE4）在卵巢癌和子宫内膜癌中均过度表达。卵巢癌和子宫内膜癌患者血清中脱落的 HE4 蛋白水平升高。在良性妇科疾病中，HE4 的升高频率低于肿瘤标志物 125（CA 125），并且在缺乏 CA 125 表达的一部分子宫内膜癌和卵巢癌中发现。因此，HE4 已成为一种重要的生物标志物，可与 CA 125 联合用于鉴别良性和恶性盆腔肿块，监测治疗反应，并检测卵巢癌和子宫内膜癌的复发。“卵巢恶性肿瘤风险算法”（ROMA）结合了 CA 125、HE4 和绝经状态，以区分良性和恶性附件肿块，并已获得美国食品和药物管理局的批准，以帮助将可能患有卵巢癌的患者转介给专门的妇科肿瘤医生进行手术。HE4 还有望提高 CA 125 检测早期卵巢癌的敏感性。在这篇综述中，我们讨论了 HE4 的发现和生物学意义，并评估了关于 HE4 作为卵巢癌和子宫内膜癌生物标志物的可用证据。
相似文献
1
The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomas.HE4 在评估上皮性卵巢癌和子宫内膜癌中的新兴作用。
Oncology (Williston Park). 2013 Jun;27(6):548-56.
2
Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management.血清人附睾蛋白 4 和卵巢恶性肿瘤算法作为上皮性卵巢癌管理的新的诊断和预后工具。
Cancer Epidemiol Biomarkers Prev. 2011 Dec;20(12):2496-506. doi: 10.1158/1055-9965.EPI-11-0635. Epub 2011 Oct 25.
3
Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.评估 HE4、CA125、卵巢恶性肿瘤风险算法（ROMA）和恶性肿瘤指数（RMI）在盆腔肿块患者中作为上皮性卵巢癌的诊断工具。
Gynecol Oncol. 2012 Nov;127(2):379-83. doi: 10.1016/j.ygyno.2012.07.106. Epub 2012 Jul 24.
4
Evaluation of human epididymis protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA) as diagnostic tools of type I and type II epithelial ovarian cancer in Japanese women.评估人附睾蛋白4（HE4）和卵巢恶性肿瘤风险算法（ROMA）作为日本女性I型和II型上皮性卵巢癌诊断工具的价值。
Tumour Biol. 2015 Feb;36(2):1045-53. doi: 10.1007/s13277-014-2738-7. Epub 2014 Oct 19.
5
HE4 in the differential diagnosis of ovarian masses.HE4在卵巢肿物鉴别诊断中的应用
Clin Chim Acta. 2015 Jun 15;446:147-55. doi: 10.1016/j.cca.2015.03.047. Epub 2015 Apr 16.
6
M-CSF in a new biomarker panel with HE4 and CA 125 in the diagnostics of epithelial ovarian cancer patients.M-CSF与HE4和CA 125组成的新型生物标志物组合用于上皮性卵巢癌患者的诊断。
J Ovarian Res. 2015 May 3;8:27. doi: 10.1186/s13048-015-0153-3.
7
Comparison of HE4, CA125, and Risk of Ovarian Malignancy Algorithm in the Prediction of Ovarian Cancer in Korean Women.HE4、CA125及卵巢恶性肿瘤风险算法在韩国女性卵巢癌预测中的比较
J Korean Med Sci. 2015 Dec;30(12):1777-83. doi: 10.3346/jkms.2015.30.12.1777. Epub 2015 Nov 30.
8
Diagnostic Performance of Serum Human Epididymis Protein 4 (HE4) for Prediction of Malignancy in Ovarian Masses.血清人附睾蛋白4（HE4）对卵巢肿物恶性病变预测的诊断效能
Asian Pac J Cancer Prev. 2019 Apr 29;20(4):1103-1108. doi: 10.31557/APJCP.2019.20.4.1103.
9
HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses - a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population.人附睾蛋白4、癌抗原125、恶性风险算法和恶性风险指数与复杂盆腔肿块——澳大利亚人群盆腔肿块术前评估中的前瞻性比较
Aust N Z J Obstet Gynaecol. 2015 Oct;55(5):493-7. doi: 10.1111/ajo.12363. Epub 2015 Jul 14.
10
Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer: a meta-analysis.卵巢恶性肿瘤风险算法是否优于人附睾蛋白 4 和 CA125 预测上皮性卵巢癌：一项荟萃分析。
BMC Cancer. 2012 Jun 19;12:258. doi: 10.1186/1471-2407-12-258.
引用本文的文献
1
Ultrasonography and Biomarkers in the Diagnostic Evaluation of Peritoneal Tuberculosis: A Case Series Analysis.超声检查及生物标志物在腹膜结核诊断评估中的应用：病例系列分析
Diagnostics (Basel). 2025 Aug 11;15(16):2008. doi: 10.3390/diagnostics15162008.
2
Utilizing Serum-Derived Lipidomics with Protein Biomarkers and Machine Learning for Early Detection of Ovarian Cancer in the Symptomatic Population.利用血清脂质组学结合蛋白质生物标志物和机器学习对有症状人群进行卵巢癌早期检测。
Cancer Res Commun. 2025 Sep 1;5(9):1516-1529. doi: 10.1158/2767-9764.CRC-25-0140.
3
HE4 as a Prognostic Biomarker of Major Adverse Cardiovascular Events in Patients with Abdominal Aortic Aneurysm: A Canadian Prospective Observational Study.人附睾蛋白4作为腹主动脉瘤患者主要不良心血管事件的预后生物标志物：一项加拿大前瞻性观察研究。
Biomedicines. 2025 Jun 26;13(7):1562. doi: 10.3390/biomedicines13071562.
4
The NF-κB-HE4 axis: A novel regulator of HE4 secretion in ovarian cancer.核因子κB-人附睾蛋白4轴：卵巢癌中人附睾蛋白4分泌的新型调节因子。
PLoS One. 2024 Dec 2;19(12):e0314564. doi: 10.1371/journal.pone.0314564. eCollection 2024.
5
Diagnostic performance of a modified O-RADS classification system for adnexal lesions incorporating clinical features.纳入临床特征的改良O-RADS分类系统对附件区病变的诊断效能
Abdom Radiol (NY). 2025 Feb;50(2):953-965. doi: 10.1007/s00261-024-04538-8. Epub 2024 Aug 20.
6
Autoantibodies, antigen-autoantibody complexes and antigens complement CA125 for early detection of ovarian cancer.自身抗体、抗原-自身抗体复合物和抗原补充 CA125 用于早期检测卵巢癌。
Br J Cancer. 2024 Mar;130(5):861-868. doi: 10.1038/s41416-023-02560-z. Epub 2024 Jan 9.
7
Roles of Antimicrobial Peptides in Gynecological Cancers.抗菌肽在妇科癌症中的作用。
Int J Mol Sci. 2022 Sep 3;23(17):10104. doi: 10.3390/ijms231710104.
8
Machine learning algorithms enhance the specificity of cancer biomarker detection using SERS-based immunoassays in microfluidic chips.机器学习算法提高了基于表面增强拉曼光谱（SERS）的微流控芯片免疫分析检测癌症生物标志物的特异性。
RSC Adv. 2019 Jan 15;9(4):1859-1868. doi: 10.1039/c8ra08930b. eCollection 2019 Jan 14.
9
Serum Human Epididymis Protein 4 as a Prognostic Marker in Cervical Cancer.血清人附睾蛋白 4 作为宫颈癌的预后标志物。
Cancer Control. 2022 Jan-Dec;29:10732748221097778. doi: 10.1177/10732748221097778.
10
Research and Implementation of Mobile Internet Management Optimization and Intelligent Information System Based on Smart Decision.基于智能决策的移动互联网管理优化与智能信息系统的研究与实现。
Comput Intell Neurosci. 2021 Dec 9;2021:5144568. doi: 10.1155/2021/5144568. eCollection 2021.
本文引用的文献
1
A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value.采用卵巢癌风险算法（ROCA）的 2 阶段卵巢癌筛查策略可识别早期发病癌症，并显示出较高的阳性预测值。
Cancer. 2013 Oct 1;119(19):3454-61. doi: 10.1002/cncr.28183. Epub 2013 Aug 26.
2
HE4 (WFDC2) Promotes Tumor Growth in Endometrial Cancer Cell Lines.HE4 (WFDC2) 促进子宫内膜癌细胞系的肿瘤生长。
Int J Mol Sci. 2013 Mar 15;14(3):6026-43. doi: 10.3390/ijms14036026.
3
Differentiating stage 1 epithelial ovarian cancer from benign ovarian tumours using a combination of tumour markers HE4, CA125, and CEA and patient's age.联合肿瘤标志物 HE4、CA125 和 CEA 及患者年龄区分 1 期上皮性卵巢癌与良性卵巢肿瘤。
Gynecol Oncol. 2013 Jun;129(3):467-71. doi: 10.1016/j.ygyno.2013.03.001. Epub 2013 Mar 13.
4
A comparison between an ultrasound based prediction model (LR2) and the risk of ovarian malignancy algorithm (ROMA) to assess the risk of malignancy in women with an adnexal mass.基于超声的预测模型（LR2）与卵巢恶性肿瘤风险算法（ROMA）在评估附件包块女性恶性肿瘤风险中的比较。
Gynecol Oncol. 2013 May;129(2):377-83. doi: 10.1016/j.ygyno.2013.01.018. Epub 2013 Jan 27.
5
Identification of human epididymis protein-4 as a fibroblast-derived mediator of fibrosis.鉴定人附睾蛋白 4 为成纤维细胞来源的纤维化介质。
Nat Med. 2013 Feb;19(2):227-31. doi: 10.1038/nm.2989. Epub 2013 Jan 27.
6
Human epididymis protein 4 for differential diagnosis between benign gynecologic disease and ovarian cancer: a systematic review and meta-analysis.人附睾蛋白 4 用于良恶性妇科疾病鉴别诊断及卵巢癌中的研究：系统评价与荟萃分析。
Eur J Obstet Gynecol Reprod Biol. 2013 Mar;167(1):81-5. doi: 10.1016/j.ejogrb.2012.10.036. Epub 2012 Dec 7.
7
Can the preoperative HE4 level predict optimal cytoreduction in patients with advanced ovarian carcinoma?术前 HE4 水平能否预测晚期卵巢癌患者的最佳肿瘤细胞减灭术效果？
Gynecol Oncol. 2013 Mar;128(3):579-83. doi: 10.1016/j.ygyno.2012.11.040. Epub 2012 Dec 7.
8
The role of novel biomarker HE4 in endometrial cancer: a case control prospective study.新型生物标志物人附睾蛋白4在子宫内膜癌中的作用：一项病例对照前瞻性研究。
Tumour Biol. 2013 Feb;34(1):571-6. doi: 10.1007/s13277-012-0583-0. Epub 2012 Nov 20.
9
Preoperative HE4 expression in plasma predicts surgical outcome in primary ovarian cancer patients: results from the OVCAD study.术前血浆 HE4 表达可预测原发性卵巢癌患者的手术结局：来自 OVCAD 研究的结果。
Gynecol Oncol. 2013 Feb;128(2):245-51. doi: 10.1016/j.ygyno.2012.11.023. Epub 2012 Nov 21.
10
Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome.人附睾蛋白 4 作为一种血清标志物用于诊断子宫内膜癌和预测临床预后。
Clin Chem Lab Med. 2012 Dec;50(12):2189-98. doi: 10.1515/cclm-2011-0757.
Zotero 插件